SLV-330

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H26ClN5O2S
Molecular Weight	459.992
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN\C(=N/S(=O)(=O)N1CCCCC1)N2C[C@@H](C(=N2)C3=CC=C(Cl)C=C3)C4=CC=CC=C4

InChI

InChIKey=VXVYAAXIGIEBPP-HXUWFJFHSA-N

InChI=1S/C22H26ClN5O2S/c1-24-22(26-31(29,30)27-14-6-3-7-15-27)28-16-20(17-8-4-2-5-9-17)21(25-28)18-10-12-19(23)13-11-18/h2,4-5,8-13,20H,3,6-7,14-16H2,1H3,(H,24,26)/t20-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H26ClN5O2S
Molecular Weight	459.992
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:48:32 GMT 2023` Edited by `admin` on `Sat Dec 16 10:48:32 GMT 2023`
Record UNII	9KNB4W7WNH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SLV-330

Code

English

SLV330

Code

English

(4S)-5-(4-CHLOROPHENYL)-N-METHYL-4-PHENYL-N'-(1-PIPERIDYLSULFONYL)-3,4-DIHYDROPYRAZOLE-2-CARBOXAMIDINE

Systematic Name

English

1H-PYRAZOLE-1-CARBOXIMIDAMIDE, 3-(4-CHLOROPHENYL)-4,5-DIHYDRO-N-METHYL-4-PHENYL-N'-(1-PIPERIDINYLSULFONYL)-, (4S)-

Systematic Name

English

(-)-(4S)-3-(4-CHLOROPHENYL)-N-METHYL-4-PHENYL-N'-((PIPERIDIN-1-YL)SULFONYL)-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDINE

Systematic Name

English

Code System Code Type Description

CAS

505031-78-7

Created by admin on Sat Dec 16 10:48:32 GMT 2023 , Edited by admin on Sat Dec 16 10:48:32 GMT 2023

PRIMARY

FDA UNII

9KNB4W7WNH

Created by admin on Sat Dec 16 10:48:32 GMT 2023 , Edited by admin on Sat Dec 16 10:48:32 GMT 2023

PRIMARY

PUBCHEM

11719546

Created by admin on Sat Dec 16 10:48:32 GMT 2023 , Edited by admin on Sat Dec 16 10:48:32 GMT 2023

PRIMARY

Related Record Type Details


					9KNB4W7WNH

SLV-330

ACTIVE MOIETY

Comments:

In the present study, our aim was to investigate whether the CB1R antagonist SLV330 could reduce ethanol and nicotine self-administration and cue-induced reinstatement of ethanol and nicotine seeking behavior in Wistar rats. The CB1 antagonist SLV330 was effective in reducing ethanol self-administration at a lowest effective dose (LED) of 10 mg/kg (p.o.) and reinstatement of ethanol seeking at a LED of 3 mg/kg (p.o.). SLV330 was also effective in reducing nicotine self-administration and reinstatement of nicotine seeking, although at a LED of 10 mg/kg (p.o.). Finally, SLV330 decreased time delay-dependent anticipatory responding (LED of 3.0 mg/kg, p.o.), indicating an increased inhibitory control.


					9KNB4W7WNH

SLV-330

ACTIVE MOIETY

Comments:

Mechanism of Action: Undefined mechanism; Highest Development Phase: Preclinical CNS disorders; Most Recent Events: 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie, 29 Apr 2008 Preclinical development is ongoing